Mucoadhesive Nanoparticles for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face challenges in achieving controlled and sustained release of therapeutic agents at mucosal sites due to rapid clearance and low bioavailability, particularly for ocular applications, where topical formulations suffer from low ocular bioavailability and frequent administration is required, leading to side effects and poor patient compliance.
Innovation Solution
Development of mucoadhesive nanoparticle delivery systems comprising amphiphilic macromolecules with a hydrophobic core and hydrophilic shell, where the hydrophilic portion is functionalized with mucosal targeting moieties like phenylboronic acid derivatives, allowing for controlled targeting and adhesion at mucosal sites without compromising stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical formulations are administered frequently to achieve therapeutic efficacy, then drug delivery effectiveness is improved, but patient compliance deteriorates and side effects increase
Solution Approach 1:
The patent applies preliminary action by incorporating mucoadhesive polymers into the nanoparticle formulation before administration. These polymers pre-establish adhesion to the ocular mucosa, ensuring that the drug remains at the target site for extended periods and eliminating the need for frequent re-dosing, thus improving patient compliance while maintaining therapeutic efficacy.
2Duration of action of moving object
If nanoparticles are designed with mucoadhesive properties for sustained release, then drug retention at mucosal site is improved, but particle stability may deteriorate
Solution Approach 1:
The patent applies local quality by creating a core-shell nanoparticle structure where the core maintains drug encapsulation and structural stability, while the shell contains mucoadhesive polymers that provide sustained release properties. This spatial differentiation allows the nanoparticle to maintain stability during circulation while achieving extended drug retention at the mucosal site through the adhesive shell layer.
Solution Approach 2:
The patent applies composite materials by combining biodegradable polymer cores with mucoadhesive polymer shells to create nanoparticles that exhibit both structural stability and sustained mucoadhesive release properties. The composite structure integrates the stabilizing function of the core with the retention function of the adhesive shell, resolving the contradiction between stability and duration of action.
3Quantity of substance
If drug loading capacity is increased in nanoparticles, then therapeutic efficacy is improved, but drug release control may deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically adjusting the molecular weight, composition ratio, and crosslinking degree of the mucoadhesive polymers in the nanoparticle shell. These parameter modifications enable the formulation to achieve high drug loading capacity while maintaining controlled release kinetics, as the optimized polymer parameters create an balanced matrix that holds both high drug quantity and regulated release profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mucoadhesive nanoparticles demonstrate enhanced drug loading capacity and sustained release of therapeutic agents for extended periods, improving bioavailability and reducing the frequency of administration, thereby enhancing therapeutic efficacy and patient compliance.
Implementation Method 1
The macromolecules are capable of self-assembly to form nanoparticles
Implementation Method 2
The hydrophilic portion is functionalized with mucosal targeting moieties like phenylboronic acid derivatives
Implementation Method 3
mucoadhesive nanoparticle delivery systems comprising amphiphilic macromolecules with a hydrophobic core and hydrophilic shell, where the hydrophilic portion is functionalized with mucosal targeting moieties
Data Source
AI summary
The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.